Last Updated : June 9, 2023
CADTH reviews drugs and makes reimbursement recommendations to Canada's federal, provincial, and territorial public drug programs, with the exception of Quebec, to guide their drug reimbursement decisions.
CADTH provides advice to the drug programs on the appropriate place in therapy for the drugs within a particular therapeutic area, including the impact of new drugs on the sequencing of treatments for the purposes of reimbursement.
Procedures for CADTH Non-Sponsored Reimbursement Reviews
Procedures for CADTH Streamlined Drug Class Reviews
A customized review of a health technology. It may consist of one, or a combination, of the following: an environmental scan, a rapid review, a clinical review, a pharmacoeconomic review, and a review of patient perspectives, and it may also include the legal, ethical, social, implementation, environmental, and policy implications of the health technology. Appropriate use recommendations are provided where applicable.
Read the following process documents for more information about the services included within the Health Technology Review program. Process documents include details on each service, including how topics are identified and how each product is produced.
A CADTH Reference List is a list of references on a specific health care topic, with summary of abstracts and links to full-text documents when available.
Read the Reference List Process document for more information about this CADTH service.
A high-level summary of a new or emerging health technology likely to have a significant impact on the delivery of health care in Canada.
Read the Horizon Scan process document for more information about the CADTH Horizon Scanning Service, including how topics are identified and how each Horizon Scan product is produced:
Offers pharmaceutical companies advice on their early drug development plans from a health technology assessment perspective.